Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Core Scientific, Inc./txCORZ · Entity 389 | See remarks | October 12, 2026 | October 14, 2026 |
| FLIR SYSTEMS INCFLIR · Entity 139418 | Sr VP, General Counsel and Sec | March 15, 2019 | March 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Core Scientific, Inc./tx
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,159,668 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 10,000 · Balance 1,159,668 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.98 to $15.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 700,000 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 700,000 F3: Represents shares held by a grantor retained annuity trust of which the Reporting Person is the sole trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.98 to $15.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F3: Represents shares held by a grantor retained annuity trust of which the Reporting Person is the sole trustee.
FLIR SYSTEMS INC
Report date March 15, 2019 · Filed March 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,526 |
Ending reported balance
After 2019-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-15 · Exercise / conversion · Acquired 5,000 · Balance 29,526 Row 2 · 2019-03-15 · Sale · Disposed 5,000 · Balance 24,526 |
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.75 · Expires 2026-04-28 | Direct | 54,000 |
Reported balance
After 2019-03-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-15 · Exercise / conversion · Disposed 5,000 · Balance 54,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2026 Filed Apr 15, 2026 20:02 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 9,600 | $18.61 | $178,650.24 |
DisclosureSEC source: 0000905148-26-001687 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,027,489 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.94 to $18.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:32 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 10,000 | $16.49 | $164,865.00 |
DisclosureSEC source: 0000905148-26-001596 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,037,089 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.285 to $16.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 00:25 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 10,000 | $15.25 | $152,523.00 |
DisclosureSEC source: 0000905148-26-001502 · form4.xml · nonDerivative · entry 3 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,047,089 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.98 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| March 31, 2026 Filed Apr 3, 2026 00:25 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 97,652 | $14.96 | $1,460,873.92 |
DisclosureSEC source: 0000905148-26-001502 · form4.xml · nonDerivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,057,089 F2 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| March 31, 2026 Filed Apr 3, 2026 00:25 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 216,734 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001502 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154,741 F1 · kind: Represents a performance-based restricted stock unit ("PSU") grant. The Reporting Person was granted PSUs on April 28, 2025 that vest based on the satisfaction of specified performance criteria, provided that the Reporting Person continues to provide service to the Issuer through the end of the applicable measurement period. Effective as of March 31, 2026, in accordance with the terms of the applicable PSUs, the Compensation Committee of the Board of Directors of the Issuer certified the level of satisfaction of the applicable prescribed performance criteria and approved the settlement of such PSUs. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:23 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 139,873 | $15.08 | $2,109,284.84 |
DisclosureSEC source: 0000905148-26-000034 · form4.xml · nonDerivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,938,007 F3 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:23 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 55,758 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000034 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,077,880 F1 · kind: Represents the acquisition of additional performance-based restricted stock units in connection with the 300% vesting of the second installment of the Reporting Person's performance-based restricted stock units granted on July 19, 2024, and previously reported at 100% vesting in the Form 4 filed by the Reporting Person on July 22, 2024. F2 · balance_after: Reported amount reflects the acquisition of 694 shares of Common Stock that the Reporting Person received on October 27, 2025 on an involuntary basis for no consideration in an in-kind distribution on a pro rata basis from a reserve of shares of Common Stock held for certain claims settlement matters in connection with previous bankruptcy proceedings of the Issuer, which was exempt from Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16a-9 under the Exchange Act. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 21:05 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GiftTranche 1 Warrants · Derivative | 20,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0000905148-25-004292 · form4.xml · derivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,133 Underlying: Common Stock · 20,000 shares Expires 2027-01-23 F1 · kind: Reflects a charitable donation. F2 · derivative.exercise_date: Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $6.81 per share, subject to certain adjustments. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:30 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 8,228 | $17.94 | $147,610.32 |
DisclosureSEC source: 0000905148-25-003490 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,021,428 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:39 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 11,805 | $14.13 | $166,804.65 |
DisclosureSEC source: 0000905148-25-003059 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,029,656 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 17:14 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 8,228 | $17.07 | $140,451.96 |
DisclosureSEC source: 0000905148-25-002333 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,041,461 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 20:14 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 7,759 | $12.39 | $96,141.77 |
DisclosureSEC source: 0000905148-25-002261 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,049,689 F1 · kind: Represents shares sold to satisfy tax obligations pursuant to a pre-existing instruction upon the vesting of restricted stock units. F2 · balance_after: Reported amount reflects the acquisition of 7,346 shares of Common Stock that the Reporting Person received on June 17, 2025 on an involuntary basis for no consideration in an in-kind distribution on a pro rata basis from a reserve of shares of Common Stock held for certain claims settlement matters in connection with previous bankruptcy proceedings of the Issuer, which was exempt from Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16a-9 under the Exchange Act. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 23:04 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 50,000 | $12.31 | $615,745.00 |
DisclosureSEC source: 0000905148-25-002017 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,050,102 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:33 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 60,000 | $11.33 | $679,884.00 |
DisclosureSEC source: 0000905148-25-001992 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100,102 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.1473 to $11.6369, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:43 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 50,000 | $11.23 | $561,585.00 |
DisclosureSEC source: 0000905148-25-001929 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,160,102 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.2084 to $11.2578, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 23:34 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 194,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001365 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,210,102 F1 · shares: Represents an annual restricted stock unit ("RSU") grant. One-third of the RSUs will vest on April 15, 2026, and the remaining two-thirds of the RSUs will vest in eight substantially equal quarterly installments thereafter, provided that the Reporting Person continues to provide service to the Issuer on each vesting date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:25 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 7,921 | $7.52 | $59,580.97 |
DisclosureSEC source: 0000905148-25-001045 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,015,502 F1 · kind: Represents shares sold to satisfy tax obligations upon the vesting of restricted stock units. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 22:03 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 25,277 | $16.24 | $410,473.20 |
DisclosureSEC source: 0000905148-25-000226 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,023,423 F1 · kind: Represents shares sold to satisfy tax obligations upon the vesting of restricted stock units. Read SEC document |
| January 03, 2025 Filed Jan 4, 2025 01:13 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 2,949 | $14.57 | $42,961.62 |
DisclosureSEC source: 0000905148-25-000029 · form4.xml · nonDerivative · entry 3 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,048,700 F2 · kind: Represents shares sold to satisfy tax obligations upon the vesting of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 01:13 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 129,861 | $14.24 | $1,849,610.22 |
DisclosureSEC source: 0000905148-25-000029 · form4.xml · nonDerivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,051,649 F2 · kind: Represents shares sold to satisfy tax obligations upon the vesting of restricted stock units. Read SEC document |
| December 31, 2024 Filed Jan 4, 2025 01:13 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 55,758 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000029 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,181,510 F1 · kind: Represents the acquisition of additional performance-based restricted stock units in connection with the 300% vesting of the first installment of the Reporting Person's performance-based restricted stock units granted on July 19, 2024, and previously reported at 100% vesting in the Form 4 filed by the Reporting Person on July 22, 2024. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:23 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | OtherTranche 2 Warrants · Derivative | 267,301 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000905148-24-003376 · form4.xml · derivative · entry 3 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 267,301 shares Expires 2029-01-23 F2 · derivative.exercise_date: Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of the Issuer's common stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days, subject to certain adjustments. The Tranche 2 Warrants became exercisable at the option of the registered holders on July 11, 2024. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:23 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GiftTranche 1 Warrants · Derivative | 20,000 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0000905148-24-003376 · form4.xml · derivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537,133 Underlying: Common Stock · 20,000 shares Expires 2027-01-23 F1 · kind: Reflects a charitable donation. Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $6.81 per share, subject to certain adjustments. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:23 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | OtherCommon Stock | 267,301 | $0.01 | $2,673.01 |
DisclosureSEC source: 0000905148-24-003376 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,125,752 Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 21:36 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | OtherTranche 2 Warrants · Derivative | 196,977 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0000905148-24-003340 · form4.xml · derivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,301 Underlying: Common Stock · 196,977 shares Expires 2029-01-23 F1 · derivative.exercise_date: Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of the Issuer's common stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of the Issuer's common stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days, subject to certain adjustments. The Tranche 2 Warrants became exercisable at the option of the registered holders on July 11, 2024. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 21:36 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | OtherCommon Stock | 196,977 | $0.01 | $1,969.77 |
DisclosureSEC source: 0000905148-24-003340 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,858,451 Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 02:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 25,000 | $17.10 | $427,420.00 |
DisclosureSEC source: 0000905148-24-003244 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,661,474 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:45 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 11,582 | $9.41 | $109,009.78 |
DisclosureSEC source: 0000905148-24-002291 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,686,474 F1 · kind: Represents shares sold to satisfy tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price of the shares sold on the transaction date by the Issuer's broker to satisfy tax obligations upon the vesting of restricted stock units for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.24 to $9.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 20:35 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 83,637 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001947 · form4.xml · nonDerivative · entry 3 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,698,056 F3 · shares: Represents a regular annual performance-based RSU ("PSU") grant. The PSUs will vest in three substantially equal installments in the 2024, 2025 and 2026 calendar years upon the attainment of certain prescribed stock price hurdles, with certain adjustments for the 2025 and 2026 calendar years, if applicable, to allow for continued vesting eligibility to the extent the prescribed performance metrics were not achieved in a prior calendar year, provided that the Reporting Person continues to provide service to the Issuer on each vesting date. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 20:35 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 250,909 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001947 · form4.xml · nonDerivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,614,419 F2 · shares: Represents a regular annual RSU grant. 1/3 of the RSUs will vest on January 23, 2025, and the remaining 2/3 of the RSUs will vest in eight substantially equal installments on the conclusion of each calendar quarter thereafter, provided that the Reporting Person continues to provide service to the Issuer on each vesting date. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 20:35 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 1,003,633 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001947 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,363,510 F1 · shares: Represents a special one-time restricted stock unit ("RSU") grant. The RSUs will vest in substantially equal installments on each of the first four anniversaries of December 31, 2023, provided that the Reporting Person continues to provide service to the Issuer on each vesting date. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 7,321 | $9.39 | $68,714.91 |
DisclosureSEC source: 0000905148-24-001800 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,877 F1 · kind: Represents shares sold to satisfy tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.13 to $9.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:18 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 26,230 | $9.90 | $259,564.21 |
DisclosureSEC source: 0000905148-24-001724 · form4.xml · nonDerivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,198 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.0101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:18 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | SaleCommon Stock | 3,770 | $9.99 | $37,670.97 |
DisclosureSEC source: 0000905148-24-001724 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,428 F1 · kind: Represents shares sold to satisfy tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.89 to $10.345, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:09 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 24,153 | $3.24 | $78,134.96 |
DisclosureSEC source: 0000905148-24-000794 · form4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,198 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:09 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock, par value $0.00001 per share | 51,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-007645 · ownership.xml · nonDerivative · entry 3 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,751,387 F3 · price: In accordance with the Plan, holders of the Issuer's Old Common Stock as of November 16, 2023 were granted the right to participate in a rights offering (the "Rights Offering") for the purchase, on a pro rata basis, of up to $55 million of New Common Stock to be issued pursuant to the Plan. The Reporting Person purchased 51,347 shares of New Common Stock pursuant to the Rights Offering. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:09 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock, par value $0.00001 per share | 3,700,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-007645 · ownership.xml · nonDerivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,700,040 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock received their pro rata share of new common stock, par value $0.00001 per share ("New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization). The receipt of the New Common Stock in exchange for Old Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:09 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Disposition to issuerCommon Stock, par value $0.0001 per share | 3,700,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-007645 · ownership.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases. F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock received their pro rata share of new common stock, par value $0.00001 per share ("New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization). The receipt of the New Common Stock in exchange for Old Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 21:13 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | GrantTranche 2 Warrants · Derivative | 464,278 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000950170-24-016365 · ownership.xml · derivative · entry 5 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,278 Underlying: Common Stock, par value $0.00001 per share · 464,278 shares Expires 2029-01-23 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). F3 · price: (continued form footnote 2) The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. F5 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). F6 · price: (continued from footnote 5) Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. F5 · derivative.exercise_date: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). F6 · derivative.exercise_date: (continued from footnote 5) Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 21:13 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | GrantTranche 1 Warrants · Derivative | 557,133 | Not disclosed Strike: $6.81 | Not disclosed |
DisclosureSEC source: 0000950170-24-016365 · ownership.xml · derivative · entry 4 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557,133 Underlying: Common Stock, par value $0.00001 per share · 557,133 shares Expires 2027-01-23 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). F3 · price: (continued form footnote 2) The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. F5 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). F6 · price: (continued from footnote 5) Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. F5 · derivative.exercise_date: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). F6 · derivative.exercise_date: (continued from footnote 5) Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 21:13 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock, par value $0.00001 per share | 51,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016365 · ownership.xml · nonDerivative · entry 3 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,351 F4 · price: In accordance with the Plan, holders of the Issuer's Old Common Stock as of November 16, 2023 were granted the right to participate in a rights offering (the "Rights Offering") for the purchase, on a pro rata basis, of up to $55 million of New Common Stock to be issued pursuant to the Plan. The Reporting Person purchased 51,347 shares of New Common Stock pursuant to the Rights Offering. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 21:13 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock, par value $0.00001 per share | 370,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016365 · ownership.xml · nonDerivative · entry 2 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,004 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). F3 · price: (continued form footnote 2) The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 21:13 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | Disposition to issuerCommon Stock, par value $0.0001 per share | 3,700,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016365 · ownership.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases. F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). F3 · price: (continued form footnote 2) The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 21:42 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 13,119 | $0.14 | $1,836.66 |
DisclosureSEC source: 0001209191-22-059427 · doc4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · EVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700,040 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 21:12 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 13,119 | $0.18 | $2,361.42 |
DisclosureSEC source: 0001209191-22-055361 · doc4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · EVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,713,159 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:00 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 13,119 | $1.37 | $17,973.03 |
DisclosureSEC source: 0001209191-22-052344 · doc4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · EVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,726,278 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 22:29 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 13,119 | $2.12 | $27,812.28 |
DisclosureSEC source: 0001209191-22-048847 · doc4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · EVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,739,397 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:07 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 13,119 | $2.74 | $35,946.06 |
DisclosureSEC source: 0001209191-22-047701 · doc4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · EVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,752,516 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 20:58 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 1,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046321 · doc4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · EVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,765,635 F1 · shares: Represents a restricted stock unit ("RSU") grants. The RSUs vest in four equal annual installments commencing August 15, 2023, provided that the Reporting Person continues to provide service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:32 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Tax withholdingCommon Stock | 13,119 | $1.51 | $19,809.69 |
DisclosureSEC source: 0001209191-22-040711 · doc4.xml · nonDerivative · entry 1 DUCHENE TODD M · CIK 0001248745 · EVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,565,635 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.